ClinicalTrials.gg

Program

GNC-077

A development code.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Breast Neoplasms · Digestive System Neoplasms, led by Sichuan Biokin Pharmaceutical.

Furthest: phase 1, since Sep 20, 20243 company-led studies, 3 open or runningNext primary completion: Jun 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sichuan Biokin Pharmaceutical33 open or runningphase 1since Sep 20, 2024Sep 20, 2024Jun 2027phase 1 · NCT06755242

Also a collaborator on its studies: baili-bio-chengdu-pharmaceutical-co-ltd.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 20, 2024First studies: 2 phase 1 studiesFirst studyNCT06609187, NCT06612840
  2. Dec 25, 2024Phase 1 study in Digestive System NeoplasmsNCT06755242 · 20 planned · China

Ahead

  1. Jun 2027Primary completion: phase 1 study in Digestive System NeoplasmsNCT06755242

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06755242Digestive System Neoplasms · China1Not yet recruitingJun 202720
NCT06612840Carcinoma, Non-Small-Cell Lung · China1RecruitingOct 202620
NCT06609187Breast Neoplasms · China1RecruitingOct 202620

How it is read

Names in the registry

  • “GNC-077”, 3 entries

Codes read as this program: GNC077.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.